A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma

Talimogene laherparepvec (T‐VEC) is approved for the treatment of unresectable melanoma in the USA, Europe, and Australia. This phase I, multicenter, open‐label, dose de‐escalation study evaluated the safety and efficacy of T‐VEC in Japanese patients with unresectable stage IIIB–IV melanoma. Eligibl...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamazaki, Naoya, Isei, Taiki, Kiyohara, Yoshio, Koga, Hiroshi, Kojima, Takashi, Takenouchi, Tatsuya, Yokota, Kenji, Namikawa, Kenjiro, Yi, Min, Keegan, Alissa, Fukushima, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357627/
https://www.ncbi.nlm.nih.gov/pubmed/35656636
http://dx.doi.org/10.1111/cas.15450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357627/
https://www.ncbi.nlm.nih.gov/pubmed/35656636
http://dx.doi.org/10.1111/cas.15450

Ejemplares similares